Investigational drug · Phase 2
BCD-236
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple Negative Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BCD-236"
First trial start
2024
Jul 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCD-236", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BCD-236" as an intervention, largest first.
- BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerPivotal-lookingRecruiting
BiocadIndustry
NCT07108309 · 124 participants (planned) · Start Jul 15, 2024 · Primary completion Dec 2025
Drug: BCD-236; Chemotherapy · For: Triple Negative Breast Cancer
Sites: Brest, Belarus; Homyel, Belarus; Minsk, Belarus · 47 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Triple Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- FDA018-ADCPhase 31 trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.